Kornimate/medical-research-clean huggingface dataset:
multicenter study for diagnosis and treatment of perianal abscesses

Conditions: Perianal Abscess; Anal Fistulas; Incontinence

Summary: drainage of perianal abscesses is a well established treatment. traditionally its been done in general anesthesia after the swelling has been localised its been drained with a knife. after surgical intervention complications can occur with recidivism, chronic fistulas that go from the anal to the skin and sometimes the anal sphincter is damaged which can cause problems with incontinence. through ultrasound the abscess is opened under more controlled forms with a better visual overview. this is a new technique that has not been tested in larger studies. the aim with ultrasound-drainage as with traditional incision to drain the abscess so that the infected area can heal. the hypothesis is a reduction of recurrences and formation of fistulas with the use of 3d ultrasonography.

the individual patient is informed about the condition and if meets criteria is offered to take part in the study. written information and informed consent always noted. questions about the patients general medical condition is noted and if the person has had problems with perianal abscesses before.

Eligibility criteria:
inclusion criteria: * perianal abscess that needs surgical treatment, over the age of 18 exclusion criteria: * under the age of 18 or unable to understand study information because of language difficulties or dementia.

Keywords: endoanal ultrasonography drainage perianal abscess fistulas incontience
a study to evaluate the safety and effectiveness of asoprisnil and estrogen administration to postmenopausal women

Conditions: Amenorrhea; Postmenopause

Summary: the objective of this study is to determine the safety and effectiveness of 3 asoprisnil doses when administered to postmenopausal women with premarin® 0.625 mg.

the objective of this study is to determine the safety and effectiveness of asoprisnil 5, 10, and 25 mg, compared to placebo, when administered to postmenopausal women, with premarin® 0.625 mg, for 12 weeks. pharmacodynamic effects to be assessed include bleeding pattern, endometrial biopsy results, and endometrial thickness. safety assessments will include clinical laboratory results, physical examination with vital signs, pelvic and breast examinations, ultrasound results, and adverse events

Eligibility criteria:
inclusion criteria: * postmenopausal women with an intact uterus * body mass index (bmi) between 18.0 - 33.0 * good general health * endometrial thickness ≤ 4 mm by tvu * no history or suspected endometrial hyperplasia * negative urine pregnancy test * pap smear in last 6 months with no evidence of malignancy or pre-malignant changes * mammogram without suspicion of malignancy within last 6 months * endometrial biopsy with no evidence of pathologic changes within last 6 months exclusion criteria: * any abnormal lab result the study-doctor considers significant * history of severe reaction to hormone therapy * receiving hormone therapy * currently using phytoestrogenic compounds, such as red clover, black cohosh (promensil and remifemin), dong quai, ginseng and soy isoflavones * history or known or suspected cancer other than basal cell carcinoma * stenosis of the cervix * history of reproductive endocrine disorder * washout requirement for hormonal therapy not met * ovarian mass * submucus or other symptomatic fibroid which would confound efficacy

Keywords: postmenopausal amenorrhea hormone replacement therapy hrt asoprisnil
analyzing gait pattern using insole-type gait analyzer in patient with gait disturbance

Conditions: Gait Disorders, Neurologic

Summary: the goal of this clinical trial is to explore the usefulness of information from insole-type gait analyzer in adults with subjective gait and balance disorders. the main questions it aims to answer are: how useful is an insole-type gait analyzer for collecting gait data from patients with gait disturbances? researchers will explore the usefulness of collected data and does not establish a control group. participants will: participants will conduct survey and perform the timed up and go test wearing an insole-type gait analyzer.

a screening test is conducted after obtaining consent. the screening test assesses whether participants can walk independently on flat ground, following an inquiry into their baseline symptoms and signs. participants will conduct a history survey, a sarcopenia questionnaire, and the international physical activity questionnaire (ipaq). participants will wear insole-type gait analyzer and undergo the timed up and go test. the measurement values of the accelerometer and pressure sensors recorded in the insole-type gait analyzer will be examined to determine the presence of missing or outlier data. researchers will explore the data collection frequency and analysis methods to extract clinically significant data.

Eligibility criteria:
inclusion criteria: 1. adults aged 19 and over (based on the age on their national id at the time of consent) 2. adults complaining subjective gait or balance disorders 3. individuals who voluntarily agree to participate in the study and sign a consent form exclusion criteria: 1. individuals unable to walk independently on flat ground for more than 6 minutes 2. individuals who cannot read ordinary print with glasses due to visual reasons 3. individuals who cannot understand conversation even with a hearing aid due to auditory reasons 4. individuals with clinically significant disorders in the cardiovascular, gastrointestinal, respiratory, or endocrine systems 5. individuals considered clinically unsuitable for the trial by the trial manager or person in charge based on significant medical findings.

Keywords: gait analysis smart insole neurologic disorder
breast cancer during pregnancy

Conditions: Pregnancy; Breast Cancer

Summary: patients are managed clinically according to ad hoc standards and scientific knowledge by a multidisciplinary team. clinical decisions are made after a patient physician discussion. blood and tissue samples are collected. diagnostic, obstetric management surgical treatment, systemic treatment, perinatal results and follow up data are collected.


Eligibility criteria:
inclusion criteria: * patients with breast cancer diagnosed during pregnancy exclusion criteria: * patients who refuse informed consent

Keywords: pregnancy breast cancer chemotherapy surgery obstetric managment
assessment of olfactory dysfunction in sars cov-2 (covid-19) infection

Conditions: Olfactory Disorder; COVID19; SARS-CoV-2; Anosmia; Microsomia; Smell Disorder; Quality of Life

Summary: this study is designed to investigate the acuity of olfactory dysfunction in covid-19 positive patients in the united kingdom. in particular defining severity with objective testing and determining if this has any predictive value on the outcome of the sars cov-2 infection. in addition, this study will strive to determine duration / natural history of olfactory dysfunction in these patients in respect to a positive sars cov-2 diagnosis. it should also demonstrate the impact of olfactory dysfunction on patient quality of life (qol).

the main objective of this study is to evaluate olfactory acuity by means of a multidimensional assessment protocol to objectively demonstrate the severity of olfactory dysfunction in patients diagnosed with sars cov-2. the university of pennsylvania smell identification test (upsit) will be used to assess olfactory function in newly diagnosed patients and also existing patients longitudinally over a 12-month period. this is to document onset (where possible) and rate of progress of olfactory dysfunction. in relevant cases, the investigators will correlate their findings with severity of the acute respiratory distress syndrome (ards) arising as a result of the infection - characterised as mild, moderate and severe according to the berlin classification. the investigators will therefore determine if the degree of olfactory dysfunction correlates in any manner to the severity of ards developed in a positive sars cov-2 patient and if it offers any prognosticative applications. the investigators will also examine the impact of the symptom of olfactory dysfunction on patient quality of life using two validated tools known as the questionnaire of olfactory disorders for english speakers (eqod) and the snot-22 questionnaire. furthermore, outcomes will be explored and stratified in terms of age, gender and ethnicity

Eligibility criteria:
inclusion criteria: * patients who are presenting to hospital with symptoms of sars cov-2 infection. * patients who go on to develop a positive sars cov-2 test. * patients who can give a valid written informed consent. * patients who are motivated to participate in the study. * adult patients aged 18 years - 85 years. exclusion criteria: * patients who cannot give a valid written informed consent. * patients who are not willing or not motivated to participate in the study. * patients with negative sars cov-2 tests. * patients with nasal pathologies like severe deviated nasal septum, nasal masses, head trauma or previously known chronic rhinosinusitis with polyps or on medication for more than 6 months/year for at least one year for chronic rhinosinusitis. * patients with any diagnosed neurological disease known to affect olfactory function will be excluded from the study. * patients unable to read in the english language.
theraspheres treatment for unresectable hepatocarcinoma and portal vein thrombosis

Conditions: Liver Cancer; Portal Vein Thrombosis

Summary: therasphere will be administered via catheter through the hepatic artery to treat patients with hepatocellular carcinoma and portal vein thrombosis.

therasphere consists of glass microspheres containing a radioactive material called yttrium-90. therasphere is delivered into the liver tumor through a catheter placed into the hepatic artery which is the artery that provides the main blood supply to the tumor, this way delivering the radioactive material directly to the tumor and sparing the rest of the liver tissue from radiation.

Eligibility criteria:
inclusion criteria: * 18 yrs of age or older * diagnosis of hepatocellular carcinoma * portal vein thrombosis * ecog performance \< 2 -\>4 weeks since prior radiation, surgery or chemotherapy. * life expectancy \> 3 months * able to provide written informed consent process in accordance with institutional review boards guidelines. exclusion criteria: * contraindications to angiography and selective visceral catheterization. * evidence of blood flow to the lung from the liver greater than 16.5 mci * evidence of any detectable tc-99m maa flow to the stomach or duodenum, after application of established angiographic techniques to stop or mitigate such flow. * significant extrahepatic disease. * severe liver disfunction of pulmonary insufficiency. * active uncontrolled infection. * significant underlying medical or psychiatric illness. * pregnancy. patients will be excluded if they have pre-existing diarrhea/illness, or if they have a co-morbid disease or condition that would preclude safe delivery of therasphere treatment and place the patient at undue risk.

Keywords: hepatocellular carcinoma portal vein thrombosis hcc
lotemax® gel 0.5% and restasis 0.05% in participants with mild or moderate keratoconjunctivitis sicca (dry eye disease)

Conditions: Keratoconjunctivitis Sicca

Summary: this study is being conducted to investigate the safety, comfort, and tolerability of 3 treatments: loteprednol etabonate ophthalmic (lotemax®) gel 0.5 percent (%) administered twice daily (bid) with or without cyclosporine ophthalmic emulsion (restasis) 0.05% administered bid, and restasis 0.05% treatment alone for 12 weeks and at a follow-up safety visit 1 week post-treatment. this study will also investigate the relative efficacy of lotemax gel 0.5% administered bid with or without restasis 0.05% treatment administered bid and of restasis 0.05% treatment alone for the reduction of clinical signs or symptoms of keratoconjunctivitis sicca (ded) over the first 4 weeks of a 12-week treatment period and at the end of a 12-week treatment period.


Eligibility criteria:
inclusion criteria: * have been diagnosed with or treated for keratoconjunctivitis sicca (ded) within 6 months prior to screening visit (day -14). * have a baseline intraocular pressure (iop) measurement of greater than or equal to (≥) 5 millimeters of mercury (mmhg) and less than or equal to (≤) 22 mmhg in each eye, with or without anti-glaucoma therapy. * have mild to moderate ded in 1 eye or both eyes at screening visit (day -14) and randomization visit (day 0). exclusion criteria: * have a known hypersensitivity to corticosteroids, cyclosporine, fluorescein, lissamine green, topical anesthetic, or any component of either of the study drugs. * have severe ded. * have corneal erosive disease or other conditions suggestive of extensive damage of the cornea. * have a history of elevated iop, a history of glaucoma, or iop greater than (\>) 22 mmhg in either eye at the screening visit (day -14). * have had penetrating intraocular surgery in the past 12 months or require penetrating intraocular surgery during the study. * have had eyelid surgery within the 6 months prior to visit 1 (day -14) or have ded secondary to surgery. * have visible evidence of anterior lid demodex spp. infection or infestation. * have had corneal refractive surgery or corneal transplantation. * have congenitally absent lacrimal or meibomian glands or have any obstructive disease of the lacrimal glands, sarcoidosis, or any other lacrimal gland deficiency. * have a diagnosis of on-going ocular infection, active anterior blepharitis, moderate to severe pinguecula, stevens-johnson syndrome, ocular cicatricial pemphigoid, significant conjunctival scarring, ocular chemical burn, or ocular neurotrophic keratitis. * have any serious systemic disease or uncontrolled medical condition that in the judgment of the investigator could confound study assessments or limit compliance. * have a history of ocular herpetic keratitis or have had active blepharitis in the 4 weeks prior to the first dose. * have had ocular surgery (including laser) within 6 months prior to the first treatment period, or plan or require ocular surgery during the study. neodymiumdoped:yttrium aluminum garnet (nd:yag) laser posterior capsulotomy is allowed.

Keywords: dry eye disease
management of esophageal atresia with right aortic arch: is the side of approach important?

Conditions: Right Aortic Arch

Summary: esophageal atresia is associated with a right aortic arch in 2 to 13% of cases. despite previous studies, consensus on the optimal surgical approach remains lacking. this study aims to analyze the management of esophageal atresia with a right aortic arch in france over three decades, to define the most effective surgical strategy and identify associated complications.


Eligibility criteria:
inclusion criteria: * having been operated on for esophageal atresia and right aortic arch exclusion criteria: * no
[sentry] tailoring postoperative management through sentinel lymph node biopsy in low- and intermediate-risk endometrial cancer

Conditions: Endometrial Cancer; Endometrial Neoplasms; Endometrial Adenocarcinoma; Endometrial Cancer Stage I; Endometrial Cancer Stage II; Endometrial Endometrioid Adenocarcinoma; Sentinel Lymph Node; Hysterectomy; Laparoscopic Hysterectomy

Summary: while total hysterectomy without lymph node staging is standard for low- and intermediate-risk endometrial cancer, certain histopathologic factors can necessitate additional interventions. our study assesses the influence of sentinel lymph node (sln) biopsy on postoperative decision-making.


Eligibility criteria:
inclusion criteria: * age ≥18 years * histologically verified low-grade endometrioid adenocarcinoma of the endometrium (g1-g2) * figo stage ia * figo stage ib and ii when lnd is contraindicated * no contraindications for surgery * signed informed consent exclusion criteria: * • age \<18 years * presence of tumor spread outside the corpus uteri * absence of tumor invasion into the myometrium * high-grade tumor (g3) * bokhman type 2 tumor (e.g., clear cell adenocarcinoma, serous adenocarcinoma, carcinosarcoma, endometrial stromal sarcoma) * preoperative treatment of endometrial cancer including radiotherapy, systemic chemotherapy, or hormone therapy * prior pelvic or retroperitoneal lnd * history of surgeries on the uterus and uterine appendages, with exceptions such as cesarean section, tubectomy, oophorectomy, ovarian resection, ovarian biopsy, and ovarian cauterization * allergy to iodine-containing drugs * contraindications to surgical treatment * lack of signed informed consent

Keywords: endometrial cancer endometrial adenocarcinoma sentinel lymph node biopsy laparoscopic hysterectomy adjuvant therapy figo
fibre grain herb trial in type 2 diabetes

Conditions: Type 2 Diabetes

Summary: despite the availability of multiple medications for the treatment of type 2 diabetes, patients often continue to have difficulty attaining blood glucose targets and managing cardiovascular disease risk factors. recent trends in non-pharmacological therapy have created a growing public interest in dietary supplements. research by this group and others support the benefits of whole grains, viscous dietary fibre and ginseng in the management of diabetes. the current study investigates whether the co-administration of a viscous dietary fibre blend, salba (a grain rich in omega-3 fatty acids), and 2 varieties of ginseng roots will further improve blood sugar control and cardiovascular disease risk outcomes in individuals with type 2 diabetes already receiving conventional treatments. patients with type 2 diabetes receiving the recommended intervention in accordance with the canadian diabetes association guidelines will be enrolled in a 6-month clinical study. half of the participants will be randomly assigned to a 4-component intervention that comprises the co-administration of these four dietary/herbal supplements in addition to their usual treatment regimen; the other half will continue their usual treatment regimen in addition to taking high-oat fiber and wheat bran supplements. the investigators hypothesize that an intensified, multi-targeted intervention with the addition of these dietary and herb components will further improve long-term blood glucose control and cardiovascular disease risk factors beyond conventional therapy. if this combination of viscous fiber, salba and ginseng is shown to be beneficial, these remedies could complement current conventional therapy for type 2 diabetes with the goal to further improve health outcomes.


Eligibility criteria:
inclusion criteria: * type 2 diabetes medically diagnosed for at least 6-months prior to randomization * hba1c (glycated hemoglobin) between 6.3% and 8.5% at screening * bmi \< 35 kg/m2 exclusion criteria: * insulin therapy * blood pressure ≥ 160/100 mmhg * serum triglyceride \>4.5mmol/l * history of major cardiovascular events (stroke or myocardial infarction) * gastrointestinal, liver or kidney disease * consumption of alcohol \>2 drinks/day * current tobacco smokers * taking the following medications: herbs or supplements that may affect primary or secondary outcomes, monoamine oxidase inhibitors (maois) antidepressants and/or anticoagulant therapy * women with hormone sensitive tumors/conditions
a randomized controlled trial of oral acetaminophen for analgesic control after transvaginal oocyte retrieval

Conditions: Pain

Summary: current standard of care is no pretreatment medications before the egg retrieval, and the investigators would like to evaluate if preoperative tylenol improves procedure and post procedure pain control over the current practice (no pre-treatment). specifically, this study will compare tylenol with a placebo when given before retrieval procedures. the investigators believe that if tylenol can offer better analgesic relief than no pretreatment medications, then it may reduce the amount of narcotics needed by patients during and after the procedure and contribute to better patient satisfaction. . this study will enroll 100 participants all from university of alabama at birmingham (uab).

the current standard of care for oocyte retrieval in ivf involves fentanyl, propofol, as well as oxycodone. however, there exists little data of alternatives to narcotic medications for analgesic purposes in oocyte retrieval procedures. a retrospective study published in 2013 showed potential for nsaid's, specifically ketorolac, to significantly improve pain scores in women undergoing oocyte retrieval. it was also shown that the use of these medications did not significantly alter pregnancy rate, live birth rate, or miscarriage rate in these patients. few other studies have delved into the question of anesthetics for oocyte retrievals except a prospective study in 2006. this study shows that no significant difference in pregnancy rates of implantation occurs with the use of acetaminophen and diclofenac vs. acetaminophen alone if given post-operatively. however, pain was not measured in this study for either group. therefore, it is clear that there exists limited data on the subject of analgesics used in oocyte retrievals for in vitro fertilization and that more exploration into alternative medications is required to find the most effective and least harmful option.

Eligibility criteria:
inclusion criteria: * english speaking * undergoing transvaginal oocyte retrieval procedure exclusion criteria: * acetaminophen allergy * opioid dependency

Keywords: analgesic pain control ivf tylenol acetaminophen egg retrieval iv vitro fertilization
effect of laser and potassium nitrate application on the sensitivity control in bleached teeth

Conditions: Dentin Sensitivity

Summary: to investigate the effects of desensitizing agents on the dental bleaching process, testing the hypothesis that they may control dental sensitivity.

the objective of this double blind, randomized and controlled clinical study, was to evaluate the efficacy of potassium nitrate / sodium fluoride (kno3 / kf) gel associated with lllt (low level light therapy) on teeth that were exposed to 35% hydrogen peroxide during 3 weeks of bleaching treatment. methods: 50 volunteers were evaluated through the split-mouth model, where the hemiarcates were randomized and later allocated in one of the experimental groups: g1 (negative control)- group with no desensitizing treatment, only bleached; g2 (positive control)- group treated with lllt + placebo gel; g3- group treated with placebo laser application + 5% kno3 / 2% kf gel; and g4- group treated with lllt + 5% kno3 / 2% kf gel.

Eligibility criteria:
inclusion criteria: * absence of active carious lesions; * never undergone bleaching therapy; * good oral hygiene; * do not present hypersensitivity; * do not smoke; * not being pregnant; * presence of at least 28 teeth in oral cavity. exclusion criteria: * presence of periodontal disease; * presence of cracks or fractures; * presence of restorations and prostheses; * presence of gastroesophageal dysfunction; * patients with severe internal dental dimming; * presence of periodontal disease; * presence of dentin exposure in anterior and/or posterior teeth.